Clinical trial
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Disease Phase IIa Open-Label Clinical Trial and Associated Mechanistic Studies
NCT07281456 is registered in ClinicalTrials.gov with National Institute of Dental and Craniofacial Research (NIDCR) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Disease Phase IIa Open-Label Clinical Trial and Associated Mechanistic Studies
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 18, 2025
- Completion date
- December 15, 2030
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.